EP 42

Biologic Immunogenecity

Biologics have revolutionized modern medicine, but they carry a silent risk called immunogenicity, where the patient's immune system sees the therapeutic protein as foreign. This episode delves into the factors that drive this immune response and the sophisticated testing required to mitigate it. The consequences of immunogenicity can be disastrous, leading to treatment failure, safety issues, and pharmacokinetic problems.

biologicsimmunogenicityanti-drug antibodiesneutralizing antibodiesbioanalytical mandatemolecular engineering

play_arrowListen to episode

Key Concepts

Immunogenicity

Immunogenicity is the ability of a substance to trigger an immune response.
It is a major concern for biologic drugs, as it can lead to treatment failure, safety issues, and pharmacokinetic problems.

Anti-Drug Antibodies (ADAs)

ADAs are antibodies that are produced in response to a biologic drug.
They can lead to treatment failure, safety issues, and pharmacokinetic problems.

Neutralizing Antibodies (NABs)

NABs are a subset of ADAs that directly inhibit the drug's biological activity.
They are the most clinically relevant subset of ADAs.

Bioanalytical Mandate

The bioanalytical mandate requires a rigorous multi-tier testing system to measure the response.
The testing system includes screening, confirmatory, and characterization assays.

Molecular Engineering

Molecular engineering involves editing out the T cell epitopes that cause immunogenicity.
It is a strategy used to design out immunogenicity from day one.

Episode Summary

check_circleBiologics are complex, targeted proteins that have changed the game in modern medicine, but they carry a risk of immunogenicity.
check_circleImmunogenicity occurs when the patient's immune system sees the therapeutic protein as foreign, leading to the production of anti-drug antibodies (ADAs).
check_circleADAs can lead to treatment failure, safety issues, and pharmacokinetic problems, and are a major concern for biologic drugs.
check_circleThe incidence of ADA generation can be astonishingly high, with some therapies having an incidence of over 90%.
check_circleThe factors that drive immunogenicity include the molecule itself, the patient, and the treatment decisions, such as route of administration and dosing.
check_circleThe bioanalytical mandate requires a rigorous multi-tier testing system to measure the response, including screening, confirmatory, and characterization assays.
check_circleThe testing system is designed to detect neutralizing antibodies (NABs), which are the most clinically relevant subset of ADAs.
check_circleThe industry is moving towards designing out immunogenicity from day one, using strategies such as molecular engineering, stealth, and AI-powered prediction.
check_circleAI algorithms can predict the risk of immunogenicity based on the drug's amino acid sequence and the patient's genetic code.
check_circleThe ultimate goal is to use a patient's genetics to pick their therapy, and to design molecules that not only avoid immunogenicity but also include elements that train the immune system to accept the drug.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.